Table 6.
Published studies on the use of DEX implant for radiation maculopathy
| Reference | Study design | No of eyes | Previous treatment | Primary treatment | Follow-up | Retreatment | BCVA | CMT | Complications |
|---|---|---|---|---|---|---|---|---|---|
| Baillif et al63 | Retrospective | 5 | None | DEX | 6.4 months | 3 eyes: 1 DEX 2 eyes: 2 DEX |
From 41 L to 2 months: 47 L | From 487.1 μm to 2 months: 331.2 μm | 1 eye IOP >25 mmHg |
| Caminal et al64 | Retrospective | 12 | 2 laser 2 VEGF IVT 5 laser + anti-VEGF IVT |
DEX | 8.2±7.8 months | 1 eye: 2 DEX | From 1±0.58 to 0.8±1.58 logMAR (P=0.091) |
From 416±263 to 254±170 μm (P=0.016) |
1 eye cataract 1 eye IOP rise |
| Russo et al65 | Retrospective comparative | 16 | NR | 8 DEX | Range 7–52 months | 2.4±0.9 DEX (24 months) (P=0.018 vs ranibizumab) |
DEX: from 0.45±0.18 to last follow-up: 0.27±0.15 logMAR (P=0.011) |
From 437±71 μm to last follow-up: 254±44 μm (P=0.012) |
NR |
| 8 ranibizumab IVT | |||||||||
| 6±1.8 ranibizumab (24 months) |
Ranibizumab: from 0.49±0.14 to last follow-up: 0.34±0.13 logMAR (P=0.012) |
From 459±81 μm to last follow-up: 243±58 μm (P=0.012) (P=0.721 vs ranibizumab) |
|||||||
| Bui et al66 | Retrospective | 2 | 16 BEV IVT +4 IVTA 7 BEV +1 IVTA |
DEX | NR | 2 DEX | From 20/60 Snellen to 3 months: unchanged From 20/400 Snellen to 3 months: unchanged |
From 456 to 238 μm after first DEX, 277 μm after second DEX From 618 to 336 μm | 1 cataract surgery 2 IOP rise |
| Seibel et al67 | Retrospective comparative | 5 DEX | None | DEX | At least 12 months | 1–2 DEX BEV (range 1–10) IVTA (range 1–3) |
DEX: 0.8 logMAR, unchanged BEV: 0.8 logMAR, 1 month, after last IVT 0.7 logMAR IVTA: 0.8 logMAR, unchanged |
DEX: from 440 μm to 4 weeks 265 μm (P=0.049 BEV: from 479 μm to 4 weeks 362 μm (P=0.01) IVTA: from 454 μm to 4 weeks 314 μm (P=0.034) |
NR |
| 38 BEV | BEV | ||||||||
| 35 IVTA | IVTA | ||||||||
| Tarmann et al68 | Retrospective | 4 | BEV IVT in 3 eyes BEV IVT + panretinal laser photocoagulation and IVTA in 1 eye |
DEX | NR | NR | From 20/100 Snellen to 2–4 weeks 20/50 to 10 weeks 20/80 Snellen to 14–17 weeks: 20/100 Snellen |
From 616 μm to 2–4 weeks: 399 μm 10 weeks: 393 μm 14–17 weeks: 568 μm |
1 eye IOP >25 mmHg |
Abbreviations: BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; NR, not reported; VEGF, vascular endothelial growth factor.